Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01406171 · ClinicalTrials.gov registry record · Phase 1

Drug Interaction Study of Isavuconazole and Midazolam

A Phase 1 study of Healthy Volunteers and Pharmacokinetics of Isavuconazole, sponsored by Astellas Pharma.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT01406171 is a Phase 1 study of Healthy Volunteers and Pharmacokinetics of Isavuconazole that has completed, run by Astellas Pharma. The registered enrollment target is 24 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01406171, a Phase 1 study of Healthy Volunteers and Pharmacokinetics of Isavuconazole, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effect of isavuconazole at steady state on the pharmacokinetics of midazolam in healthy adult subjects.

Interventions

  • DRUG Midazolam
  • DRUG Isavuconazole

Study Locations (1)

Wisconsin

  • Covance Clinical Research - Madison

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2011-05
Est. Completion 2011-06
Phase Phase 1

Sponsor

Astellas Pharma

165 total trials

What the Registry Record Tells You About NCT01406171

The ClinicalTrials.gov registry entry for NCT01406171 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (95% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Midazolam is the first listed.

NCT01406171 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT01406171 about?

NCT01406171 is a clinical study titled "Drug Interaction Study of Isavuconazole and Midazolam". The purpose of this study is to determine the effect of isavuconazole at steady state on the pharmacokinetics of midazolam in healthy adult subjects.

What is the current status of trial NCT01406171?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-05. Estimated completion is 2011-06.

What conditions does trial NCT01406171 study?

This clinical trial studies the following conditions: Healthy Volunteers, Pharmacokinetics of Isavuconazole, Pharmacokinetics of Midazolam.

What interventions are being tested in trial NCT01406171?

The interventions under investigation include: Midazolam (DRUG), Isavuconazole (DRUG).

Who is sponsoring clinical trial NCT01406171?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01406171 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.